The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Oral CBD Fails to Relieve Pain from Hand OA & PsA

Oral CBD Fails to Relieve Pain from Hand OA & PsA

September 21, 2021 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Lower doses of cannabidiol (CBD) failed to provide any meaningful reduction in pain when added to other analgesic therapy in patients with hand osteoarthritis (OA) or psoriatic arthritis (PsA) in a randomized, placebo-controlled study from Denmark.1

You Might Also Like
  • Nonsurgical Treatments Can Relieve Pain, Improve Hand Function in Thumb Carpometacarpal Joint Osteoarthritis
  • Recro Pharma’s Non-Opioid Pain Shot Fails to Get Approval from FDA
  • Bimekizumab Promising for PsA

Writing in the journal, Pain, Jonathan Vela, MD, and colleagues of Aalborg University note that CBD is increasingly used as analgesic medication despite a lack of trials examining CBD for pain management.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

They tested the effects of 12 weeks of CBD (20­–30 mg daily) vs. placebo as add-on analgesic therapy in patients with hand OA or PsA experiencing moderate pain intensity despite other pain medication.

The primary outcome was the difference between groups after 12 weeks in the change in patient-reported pain intensity during the last 24 hours on a visual analogue scale (VAS) with scores ranging from 0 mm (no pain) to 100 mm (worst pain). A total of 136 patients were randomized, with 129 included in the primary analysis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At 12 weeks, there were no statistically significant differences in pain intensity between the CBD group and the placebo group, with a mean difference of 0.23 mm on the VAS scale; 22% of patients using CBD and 21% using placebo experienced a reduction in pain intensity of more than 30 mm.

“We found neither clinically nor statistically significant effect of CBD for pain intensity in patients with hand OA and PsA when compared with placebo. Additionally, no statistically significant effects were found on sleep quality, depression, anxiety or pain catastrophizing scores,” the study team reports.

They caution that due to a lack of data on an optimal CBD dose for an analgesic effect, they chose a pragmatic dose of 20–30 mg daily.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“This dose could prove insufficient to produce the plasma concentrations required to activate relevant receptors involved in inflammation and nociception. CBD dosage regimes used in trials regarding neurological disease often surpass 1,000 mg daily, but with a significant number of side-effects. Future high quality double-blind, randomized and placebo-controlled trials are needed to further explore the possible analgesic properties of higher doses of CBD,” the researchers say.

The study was supported by grants from the Danish Psoriasis Foundation and the Danish Rheumatism Foundation. The authors have no relevant conflicts of interest.


Reference

  1. Vela J, Dreyer L, Petersen KK, et al. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: A randomized, double-blind placebo-controlled trial. Pain. 2021 Aug 27. Online ahead of print.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates Tagged With: cannabidiol (CBD), hand osteoarthritis, hand pain, Pain, PsA, Psoriatic Arthritis

You Might Also Like:
  • Nonsurgical Treatments Can Relieve Pain, Improve Hand Function in Thumb Carpometacarpal Joint Osteoarthritis
  • Recro Pharma’s Non-Opioid Pain Shot Fails to Get Approval from FDA
  • Bimekizumab Promising for PsA
  • IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)